Equities Analysts Issue Forecasts for Oncolytics Biotech Inc.’s FY2023 Earnings (TSE:ONC)

Oncolytics Biotech Inc. (TSE:ONCGet Rating) – Leede Jones Gab issued their FY2023 earnings per share estimates for Oncolytics Biotech in a note issued to investors on Monday, March 6th. Leede Jones Gab analyst D. Loe anticipates that the company will post earnings per share of ($0.36) for the year. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. Leede Jones Gab also issued estimates for Oncolytics Biotech’s FY2024 earnings at ($0.33) EPS, FY2025 earnings at ($0.31) EPS and FY2026 earnings at ($0.02) EPS.

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a C$9.00 target price on shares of Oncolytics Biotech in a research note on Monday.

Oncolytics Biotech Stock Down 5.6 %

TSE ONC opened at C$1.85 on Thursday. The company has a debt-to-equity ratio of 1.41, a current ratio of 9.05 and a quick ratio of 8.86. The stock has a market capitalization of C$109.21 million, a PE ratio of -4.20 and a beta of 1.70. Oncolytics Biotech has a 1 year low of C$1.06 and a 1 year high of C$3.10. The business’s 50-day moving average is C$2.26 and its 200 day moving average is C$2.07.

Oncolytics Biotech Company Profile

(Get Rating)

Oncolytics Biotech Inc, a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies.

See Also

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.